# Tolvaptan

## Jinarc 15mg

##### 臨採

| TAH Drug Code      | [OJIN1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OJIN1)                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Indicated for adults with autosomal dominant polycystic kidney disease (ADPKD) and eGFR greater than 25mL/min/1.73m2 with signs of rapid disease progression, to slow the growth of cysts and decline in kidney function associated with autosomal dominant polycystic kidney disease.                                                                                                                                                                        |
| Dosing             | Take twice daily. Dosage options: 45mg + 15mg, 60mg + 30mg, or 90mg + 30mg (split dose regimen). First dose 30 minutes before breakfast. Second dose can be taken with or without food. Initial: total dose 60mg (45mg on waking, 15mg after 8 hours). If tolerated, increase to 90mg daily (60mg + 30mg), then up to the target dose of 120mg daily (90mg + 30mg). At each dosage adjustment, allow at least one week interval.                              |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | Hypersensitivity to tolvaptan or any component of the product or benzazepine or benzazepine derivatives. Presence of liver enzyme elevation and/or liver damage signs or symptoms that meet the criteria for permanent discontinuation of tolvaptan before starting treatment. Anuria. Volume depletion. Hypernatremia. Unable to sense or respond to thirst. Pregnancy. Breastfeeding.                                                                       |
| Adverse Effects    | Common: Hypernatremia (0.7-25.6%), Diarrhea (13.3%), Increased thirst (12-63.7%), Nausea (8-21%), Xerostomia (7-23%), ALT/SGPT level raised, Serum bilirubin above reference range, Asthenia (9%), Dizziness (4.8-11.3%), Increased frequency of urination (69.5%), Polyuria (4-24%), Fatigue (13.6%) Serious: Hypovolemia, Gastrointestinal hemorrhage, In cirrhotic patients (10%), Hepatic failure, acute, Injury of liver, Osmotic demyelination syndrome |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tolvaptan-drug-information)                                                                                                                                                                                                                                                                                                                                                                                      |

## Jinarc 45mg

##### 臨採

| TAH Drug Code      | [OJIN4](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OJIN4)                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Indicated for adults with autosomal dominant polycystic kidney disease (ADPKD) and eGFR greater than 25mL/min/1.73m2 with signs of rapid disease progression, to slow the growth of cysts and decline in kidney function associated with autosomal dominant polycystic kidney disease.                                                                                                                                                                        |
| Dosing             | Take twice daily. Dosage options: 45mg + 15mg, 60mg + 30mg, or 90mg + 30mg (split dose regimen). First dose 30 minutes before breakfast. Second dose can be taken with or without food. Initial: total dose 60mg (45mg on waking, 15mg after 8 hours). If tolerated, increase to 90mg daily (60mg + 30mg), then up to the target dose of 120mg daily (90mg + 30mg). At each dosage adjustment, allow at least one week interval.                              |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Contraindications  | Hypersensitivity to tolvaptan or any component of the product or benzazepine or benzazepine derivatives. Presence of liver enzyme elevation and/or liver damage signs or symptoms that meet the criteria for permanent discontinuation of tolvaptan before starting treatment. Anuria. Volume depletion. Hypernatremia. Unable to sense or respond to thirst. Pregnancy. Breastfeeding.                                                                       |
| Adverse Effects    | Common: Hypernatremia (0.7-25.6%), Diarrhea (13.3%), Increased thirst (12-63.7%), Nausea (8-21%), Xerostomia (7-23%), ALT/SGPT level raised, Serum bilirubin above reference range, Asthenia (9%), Dizziness (4.8-11.3%), Increased frequency of urination (69.5%), Polyuria (4-24%), Fatigue (13.6%) Serious: Hypovolemia, Gastrointestinal hemorrhage, In cirrhotic patients (10%), Hepatic failure, acute, Injury of liver, Osmotic demyelination syndrome |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                        |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tolvaptan-drug-information)                                                                                                                                                                                                                                                                                                                                                                                      |

## Samsca 15mg

##### 臨採

| TAH Drug Code      | [OSAM](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OSAM)                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Clinically significant hypervolemic & euvolemic hyponatremia including patients w/ heart failure & syndrome of inappropriate antidiuretic hormone (SIADH).                                                                                                                                                                                                                                                                                                                                           |
| Dosing             | Adult: Initial, 15 mg QD; may increase to 30 mg QD, after at least 24 hours, to maximum of 60 mg QD; do not administer for more than 30 days. Patient should be hospitalized for initiation or reinitiation of tolvaptan therapy to evaluate therapeutic response and avoid too rapid correction of hyponatremia. Serum sodium levels should be monitored for prevention of too rapid correction of hyponatremia. (Correction of hyponatremia < 10-12 mEq/L in 24 hours, and < 18 mEq/L in 48 hours) |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Autosomal Dominant Polycystic Kidney disease (ADPKD) patients outside TFDA-approved Jinarc RMP Inability to sense or respond to thirst Hypovolemic hyponatremia Use of strong CYP3A inhibitors Anuria Allergy to tolvaptan or inactive ingredients (e.g., anaphylaxis, systemic rash)                                                                                                                                                                                                                |
| Adverse Effects    | Thirst, dry mouth, pollakiuria or polyuria, asthenia, constipation, hyperglycemia, pyrexia & anorexia.                                                                                                                                                                                                                                                                                                                                                                                               |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tolvaptan-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                             |

